Key result
Review highlights 2022 CV pharmacology advances including first-in-class drugs and fixed-dose combination therapies.
Why the study?
Cardiovascular diseases remain the leading cause of death worldwide and pharmacotherapy is often suboptimal, creating an unmet clinical need for new pharmacological strategies with greater efficacy and better safety profiles.
This review highlights key 2022 advances in cardiovascular pharmacology, including novel agents like mavacamten and tirzepatide, and new combination strategies for various cardiovascular conditions.
No takes yet. Share an insight, caveat, or question.
Offers clinicians a summary of 2022 pharmacologic advances; leaves open translation into practice pending prospective validation.
Tamargo et al. (2023) conducted a review in Cardiovascular diseases. Novel cardiovascular pharmacotherapy strategies was evaluated. This review summarizes the most relevant advances in cardiovascular pharmacology in 2022, including first-in-class drugs and fixed-dose combination therapies for various cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: